IL158649A0 - Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function - Google Patents

Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function

Info

Publication number
IL158649A0
IL158649A0 IL15864998A IL15864998A IL158649A0 IL 158649 A0 IL158649 A0 IL 158649A0 IL 15864998 A IL15864998 A IL 15864998A IL 15864998 A IL15864998 A IL 15864998A IL 158649 A0 IL158649 A0 IL 158649A0
Authority
IL
Israel
Prior art keywords
azabenzimidazole
protein kinase
based compounds
threonine protein
kinase function
Prior art date
Application number
IL15864998A
Other languages
English (en)
Original Assignee
Zentaris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentaris Gmbh filed Critical Zentaris Gmbh
Publication of IL158649A0 publication Critical patent/IL158649A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL15864998A 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function IL158649A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6014597P 1997-09-26 1997-09-26
IL13510998A IL135109A0 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
PCT/US1998/019973 WO1999016438A1 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function

Publications (1)

Publication Number Publication Date
IL158649A0 true IL158649A0 (en) 2004-05-12

Family

ID=22027657

Family Applications (4)

Application Number Title Priority Date Filing Date
IL15864998A IL158649A0 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
IL13510998A IL135109A0 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
IL135109A IL135109A (en) 1997-09-26 2000-03-15 Compounds based on azabenzamide, a method, their preparation and the pharmaceutical preparations containing them
IL158649A IL158649A (en) 1997-09-26 2003-10-29 Regulation of the activity of serine / threonine protein kinase using azabenzamide-based compounds

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL13510998A IL135109A0 (en) 1997-09-26 1998-09-23 Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
IL135109A IL135109A (en) 1997-09-26 2000-03-15 Compounds based on azabenzamide, a method, their preparation and the pharmaceutical preparations containing them
IL158649A IL158649A (en) 1997-09-26 2003-10-29 Regulation of the activity of serine / threonine protein kinase using azabenzamide-based compounds

Country Status (27)

Country Link
US (2) US6093728A (enExample)
EP (1) EP1017384B1 (enExample)
JP (1) JP2001517699A (enExample)
KR (1) KR100547929B1 (enExample)
CN (1) CN1167420C (enExample)
AR (1) AR017266A1 (enExample)
AT (1) ATE281834T1 (enExample)
AU (1) AU748849B2 (enExample)
BG (1) BG64784B1 (enExample)
BR (1) BR9812682A (enExample)
CA (1) CA2305370C (enExample)
DE (1) DE69827516T2 (enExample)
DK (1) DK1017384T3 (enExample)
ES (1) ES2230719T3 (enExample)
HU (1) HUP0004024A3 (enExample)
IL (4) IL158649A0 (enExample)
NO (1) NO325663B1 (enExample)
NZ (2) NZ503432A (enExample)
PL (1) PL191618B1 (enExample)
PT (1) PT1017384E (enExample)
RU (1) RU2230553C2 (enExample)
SK (1) SK285357B6 (enExample)
TR (1) TR200001546T2 (enExample)
TW (1) TW581815B (enExample)
UA (1) UA72448C2 (enExample)
WO (1) WO1999016438A1 (enExample)
ZA (1) ZA988797B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6919366B2 (en) * 1998-05-22 2005-07-19 Avanir Pharmaceuticals Benzimidazole derivatives as modulators of IgE
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
US6384049B1 (en) * 2000-05-25 2002-05-07 The Procter & Gamble Company Cancer treatment
DE60221804T2 (de) * 2001-03-12 2008-05-15 Avanir Pharmaceuticals, San Diego Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
WO2004024655A2 (en) 2002-09-12 2004-03-25 Avanir Pharmaceuticals Phenyl-indole compounds for modulating ige and inhibiting cellular proliferation
EP1651198A2 (en) * 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases
GB0423554D0 (en) 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
EP1962892A4 (en) * 2005-11-22 2011-10-12 Univ South Florida INHIBITION OF CELL PROLIFERATION
EP2013207B1 (en) 2006-04-26 2012-04-25 Cancer Research Technology Limited Imidazo[4,5-b]pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
JP5513118B2 (ja) 2006-10-19 2014-06-04 シグナル ファーマシューティカルズ，エルエルシー ヘテロアリール化合物、その組成物、及びプロテインキナーゼ阻害剤としてのそれらの使用
WO2008104979A2 (en) * 2007-02-28 2008-09-04 Yeda Research And Development Co. Ltd. Nuclear targeting sequences
AR066845A1 (es) 2007-06-05 2009-09-16 Takeda Pharmaceutical Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer
JP5270553B2 (ja) 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
WO2009028629A1 (ja) * 2007-08-29 2009-03-05 Takeda Pharmaceutical Company Limited 複素環化合物およびその用途
BRPI0821227A2 (pt) 2007-12-19 2015-06-16 Cancer Rec Tech Ltd Composto, composição farmacêutica, método para preparar a mesma, uso de um composto, método para tratar uma doença ou distúrbio, para inibir função de raf e para inibir proliferação celular, inibir progressão do ciclo celular, promover apoptose, ou uma combinação de um ou mais dos mesmos
GB0807609D0 (en) 2008-04-25 2008-06-04 Cancer Rec Tech Ltd Therapeutic compounds and their use
US20100184851A1 (en) * 2008-08-29 2010-07-22 University Of South Florida Inhibition of cell proliferation
US8110578B2 (en) 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8697874B2 (en) 2008-12-01 2014-04-15 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JP2012197231A (ja) * 2009-08-06 2012-10-18 Oncotherapy Science Ltd Ｔｔｋ阻害作用を有するピリジンおよびピリミジン誘導体
NZ599549A (en) 2009-10-26 2013-11-29 Signal Pharm Llc Methods of synthesis and purification of heteroaryl compounds
JP5760010B2 (ja) 2010-02-01 2015-08-05 キャンサー・リサーチ・テクノロジー・リミテッド １−（５−ｔｅｒｔ−ブチル−２−フェニル−２Ｈ−ピラゾール−３−イル）−３−［２−フルオロ−４−（１−メチル−２−オキソ−２，３−ジヒドロ−１Ｈ−イミダゾ［４，５−Ｂ］ピリジン−７−イルオキシ）−フェニル］−尿素および関連化合物ならびに治療におけるそれらの使用
EA034512B1 (ru) 2011-10-19 2020-02-14 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Лечение злокачественной опухоли ингибиторами tor-киназы
PE20141696A1 (es) 2011-12-02 2014-11-08 Signal Pharm Llc Composiciones farmaceuticas de 7-(6-(2-hidroxipropan-2-il) piridin-3-il)-1-((trans)-4-metoxiciclohexil)-3,4-dihidropirazino[2,3-b] pirazin-2(1h)-ona, una forma solida del mismo y metodos de su uso
JP6114317B2 (ja) 2012-02-24 2017-04-12 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤の組合せ療法を用いて、非小細胞肺がんを処置する方法
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
US9346812B2 (en) 2013-01-16 2016-05-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
US9650376B2 (en) 2013-03-15 2017-05-16 Knopp Biosciences Llc Imidazo(4,5-B) pyridin-2-yl amides as KV7 channel activators
HK1221174A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用於治疗癌症的包括tor激酶抑制剂和5-取代喹唑啉酮化合物的组合疗法
BR112015026257B1 (pt) 2013-04-17 2022-12-20 Signal Pharmaceuticals, Llc Uso de um composto dihidropirazino-pirazina e enzalutamida, composição farmacêutica que os compreende, e kit
EP4218763A1 (en) 2013-04-17 2023-08-02 Signal Pharmaceuticals, LLC 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one for treating glioblastoma multiforme
JP6382946B2 (ja) 2013-04-17 2018-08-29 シグナル ファーマシューティカルズ，エルエルシー ジヒドロピラジノ−ピラジンによる癌治療
WO2014172432A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
EA030726B1 (ru) 2013-04-17 2018-09-28 СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи ФАРМАЦЕВТИЧЕСКИЕ СОСТАВЫ, СПОСОБЫ, ТВЕРДЫЕ ФОРМЫ И СПОСОБЫ ПРИМЕНЕНИЯ, ОТНОСЯЩИЕСЯ К 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1H-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1H)-ОНУ
CA2909579A1 (en) 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
JP6401250B2 (ja) 2013-05-29 2018-10-10 シグナル ファーマシューティカルズ，エルエルシー ７−（６−（２−ヒドロキシプロパン−２−イル）ピリジン−３−イル）−１−（（ｔｒａｎｓ）−４−メトキシシクロヘキシル）−３，４−ジヒドロピラジノ［２，３−ｂ］ピラジン−２（１Ｈ）−オン、その固体形態の医薬組成物、及びその使用方法
EP3046929B1 (en) 2013-09-17 2019-01-16 Yeda Research and Development Co., Ltd. Erk-derived peptides and uses thereof
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
WO2015160880A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
JP2017514806A (ja) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
CN106715427A (zh) 2014-07-14 2017-05-24 西格诺药品有限公司 利用取代的吡咯并嘧啶化合物、其组合物治疗癌症的方法
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
DK3191457T3 (da) 2014-09-12 2019-10-07 Knopp Biosciences Llc BENZOIMIDAZOL-1,2-YL AMIDER SOM Kv7-KANALAKTIVATORER
MX2019015731A (es) 2017-06-22 2020-08-03 Celgene Corp Tratamiento de carcinoma hepatocelular caracterizado por infeccion por virus de hepatitis b.

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590045A (en) * 1969-09-25 1971-06-29 Smith Kline French Lab Certain substituted imidazo (4,5-b)pyridines
BE788065A (fr) 1971-08-26 1973-02-26 Degussa Nouvelles aza-benzimidazoles et procede pour leur preparation
SE422799B (sv) 1975-05-28 1982-03-29 Merck & Co Inc Analogiforfarande for framstellning av 1,3-dihydroimidazo (4,5-b)pyridin-2-oner
ES473201A1 (es) * 1977-09-26 1979-03-16 Degussa Procedimiento para la preparacion de 7-azabencimidazoles
US5217999A (en) * 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
FI924427L (fi) * 1990-04-02 1992-10-01 Pfizer Bensylfosfonsyratyrosinkinas-inhibitorer
US5302606A (en) * 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
ATE159009T1 (de) * 1991-05-10 1997-10-15 Rhone Poulenc Rorer Int Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
US6194439B1 (en) * 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
RU2155187C2 (ru) * 1992-08-06 2000-08-27 Варнер-Ламберт Компани Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека.
US5330992A (en) * 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
GB9226855D0 (en) * 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US5582995A (en) 1993-06-11 1996-12-10 The General Hospital Corporation Methods of screening for compounds which inhibit the direct binding of Ras to Raf
BR9406946A (pt) * 1993-07-06 1996-08-06 Pfizer Tetra-hidro-pirazolpiridinas bicíclicas
US5645982A (en) * 1993-08-19 1997-07-08 Systemix, Inc. Method for screening potential therapeutically effective antiviral agents
GB9501567D0 (en) * 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5880141A (en) * 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease

Also Published As

Publication number Publication date
PL191618B1 (pl) 2006-06-30
KR20010015623A (ko) 2001-02-26
IL158649A (en) 2006-12-10
CA2305370C (en) 2006-11-28
BR9812682A (pt) 2000-08-22
US6855723B2 (en) 2005-02-15
DK1017384T3 (da) 2005-01-31
AU9578198A (en) 1999-04-23
BG104356A (en) 2000-12-29
SK285357B6 (sk) 2006-11-03
HUP0004024A3 (en) 2001-10-29
CN1167420C (zh) 2004-09-22
AU748849B2 (en) 2002-06-13
NO20001555L (no) 2000-03-24
CA2305370A1 (en) 1999-04-08
KR100547929B1 (ko) 2006-02-02
DE69827516T2 (de) 2005-12-01
TR200001546T2 (tr) 2000-10-23
CN1278172A (zh) 2000-12-27
NZ503432A (en) 2002-11-26
WO1999016438A1 (en) 1999-04-08
HK1032206A1 (en) 2001-07-13
SK4152000A3 (en) 2002-02-05
IL135109A (en) 2007-07-04
ZA988797B (en) 1999-12-02
ES2230719T3 (es) 2005-05-01
HUP0004024A2 (hu) 2001-04-28
EP1017384B1 (en) 2004-11-10
AR017266A1 (es) 2001-09-05
BG64784B1 (bg) 2006-04-28
JP2001517699A (ja) 2001-10-09
NO325663B1 (no) 2008-07-07
NZ517808A (en) 2003-07-25
EP1017384A1 (en) 2000-07-12
UA72448C2 (en) 2005-03-15
ATE281834T1 (de) 2004-11-15
NO20001555D0 (no) 2000-03-24
PL339744A1 (en) 2001-01-02
RU2230553C2 (ru) 2004-06-20
TW581815B (en) 2004-04-01
PT1017384E (pt) 2005-03-31
DE69827516D1 (de) 2004-12-16
US6093728A (en) 2000-07-25
US20030181480A1 (en) 2003-09-25
IL135109A0 (en) 2001-05-20

Similar Documents

Publication Publication Date Title
IL158649A0 (en) Azabenzimidazole-based compounds for modulating serine/threonine protein kinase function
ZA988961B (en) Methods of modulating serine/threonine protein kinase function with 5-azaquinoxaline-based compounds.
EG23816A (en) Aryl fused azapolycyclic compounds
AU3363599A (en) Heterocyclic families of compounds for the modulation of tyrosine protein kinase
AU7282998A (en) Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds
GB9715892D0 (en) Heterocyclic compounds
PL338259A1 (en) Novel spiroazabicyclic heterocyclic compounds
IL132170A0 (en) Novel heterocyclic compounds
HUP0103079A3 (en) Modulating multiple lineage kinase proteins
ZA981920B (en) Novel heterocyclic compounds
AU6049399A (en) Serine/threonine protein kinases
GB9803399D0 (en) Protein kinase c
AU6421498A (en) Serine/threonine protein kinase
AU6546098A (en) Serine/threonine protein kinase
GB9713732D0 (en) Substituted triazinic compounds
GB9716101D0 (en) Fused heterocyclic compounds
ZA985448B (en) Novel heterocyclic compounds
ZA983800B (en) Novel heterocyclic compounds
ZA983669B (en) Methods of modulating serine/threonine protein kinase function with quinazoline-based compounds.
IL136872A0 (en) Organosilane compounds
GB9719237D0 (en) Heterocyclic compounds
GB9801058D0 (en) Heterocyclic compounds
GB9715735D0 (en) Heterocyclic compounds
GB9716378D0 (en) Heterocyclic compounds
GB9715734D0 (en) Heterocyclic compounds

Legal Events

Date Code Title Description
KB Patent renewed
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees